Episode Details

Succinylcholine is a short-acting, depolarizing neuromuscular blocking agent (NMBA) used as an adjunct to general anesthesia to facilitate tracheal intubation and provide skeletal muscle relaxation. Applying the 80/20 rule, the core clinical essence of succinylcholine centers on its rapid mechanism, critical safety warnings, and precise dosing.

1. Core Mechanism & Pharmacokinetics (The "20%" Driving Action)

• Mechanism: Succinylcholine competes with acetylcholine (ACh) at cholinergic receptors on the motor end-plate, depolarizing the membrane. Resistant to acetylcholinesterase, it remains bound to inhibit repolarization, causing transient muscle fasciculations followed by flaccid paralysis.
• Paralysis Order: Affects facial and glottis muscles first, then intercostals, diaphragm, and other skeletal muscles. Recovery occurs in the reverse order.
• Pharmacokinetics: Highly ionized with low lipid solubility, it distributes rapidly in extracellular space. It is hydrolyzed by plasma cholinesterase to inactive metabolites.
• Prolonged Blockade: Decreased plasma cholinesterase activity—due to genetics, liver/renal dysfunction, pregnancy, burns, or drugs (e.g., oral contraceptives)—prolongs neuromuscular blockade.

2. Boxed Warnings & Life-Threatening Risks (Critical Safety "80%")

• Severe Hyperkalemia: Contraindicated after the acute phase of major burns, multiple trauma, skeletal muscle denervation, or upper motor neuron injury. It can trigger severe hyperkalemia, peaking 7 to 10 days post-injury, causing cardiac arrest. Avoid if baseline potassium is > 5.5 mEq/L.
• Pediatric Safety: Contraindicated in patients with skeletal muscle myopathy (e.g., Duchenne's). Reserve pediatric use for emergency intubation due to risks of rhabdomyolysis and sudden hyperkalemic cardiac arrest (often presenting as peaked T-waves).
• Malignant Hyperthermia (MH): Contraindicated in patients with genetic susceptibility (RYR1 or CACNA1S variants). Inhalation anesthetics compound this risk. Continuous ETCO2 and temperature monitoring are vital for early recognition.

3. Key Clinical Dosing & Administration

• Rapid-Sequence Intubation (RSI):
  • Adults: 1.5 mg/kg IV (onset ~1 min).
  • Pediatrics (2-17 years): 1 to 1.5 mg/kg IV.
  • Infants & Neonates: 2 mg/kg IV.
• Non-Emergent Intubation:
  • Adults: 0.6 mg/kg IV (range: 0.3 to 1.1 mg/kg).
• Intramuscular (IM) Backup: Used if IV access is unavailable. Adults: 3 to 4 mg/kg (Max: 150 mg); Infants/Children: 4 to 5 mg/kg IM. Onset is 2 to 5 minutes.
• Incompatibilities: Succinylcholine is acidic (pH 3 to 4.5); do not mix with alkaline solutions (pH > 8.5).